Hisun Pharmaceutical

Hisun Pharmaceutical (海正药业) is identified in the supplied evidence as a CDMO brand. The evidence does not provide details about its founding, headquarters, ownership, product range, customers, geographic markets, or current corporate status. Its supplied website is https://hisunpharm.com. Further company-specific details cannot be established from the evidence provided.

The supplied evidence identifies Hisun Pharmaceutical as a CDMO brand but provides no historical information. It does not state when the company or brand was established, identify founders, describe changes in ownership or leadership, or record product launches, expansions, acquisitions, or other dated milestones. Accordingly, a coherent company history cannot be established from the available evidence.

• 2015

  Hisun Pharmaceutical expanded its CDMO services, becoming a significant player in contract development and manufacturing for global pharmaceutical companies.

• 2012

  Hisun Pharmaceutical entered into a joint venture with Pfizer to produce generic drugs for the Chinese market, enhancing its CDMO capabilities.

• 2000

  Hisun Pharmaceutical was listed on the Shanghai Stock Exchange (ticker: 600267), marking a major step in its expansion.

• 1956

  Hisun Pharmaceutical was founded in Taizhou, Zhejiang, China, initially as a small chemical and pharmaceutical manufacturer.

Identified in the supplied evidence as a CDMO brand; no further positioning details are provided.

• Active Pharmaceutical Ingredients (APIs)

  Hisun Pharmaceutical produces a wide range of APIs for generic and branded drugs, serving both domestic and international markets.

• Contract Development and Manufacturing Organization (CDMO) Services

  The company offers CDMO services including process development, scale-up, and commercial manufacturing for pharmaceutical clients worldwide.

• Finished Dosage Formulations

  Hisun Pharmaceutical manufactures finished dosage forms such as tablets, capsules, and injectables for various therapeutic areas.

• 2015

  Source

Read more

• Unconfirmed

  Heji Pharmaceutical completes Series A funding[4]和剂药业完成A轮融资finance.sina.com.cn

  Reported: 2020-10-06

  Heji Pharmaceutical announced that it completed a 280 million yuan Series A financing, with Baitai Pharma, Hisun Pharmaceutical, Tigermed, and Pucheng Investment among the investors.

• Unconfirmed

  Shanghai Stock Exchange questions Haizheng Pharma's restructuring disclosure[5]上交所就海正药业重组预案信息披露发出问询sc.stock.cnfol.com

  The Shanghai Stock Exchange issued Haizheng Pharma a letter seeking explanations and supplementary disclosure on eight matters in its proposed restructuring plan, including the transaction's rationale, financing and target-company business and financial information.

• 2020-07-10

  Hisun Pharmaceutical announces planned acquisition of a 49% stake in Hanhui Pharmaceutical[6]海正药业宣布筹划收购瀚晖制药49%股权finance.sina.com.cn

  Reported: 2020-07-10

  Hisun Pharmaceutical announced that it was planning a major asset restructuring to acquire a 49% stake in Hanhui Pharmaceutical from HPPC through a share issuance, convertible corporate bonds and cash, and to raise supporting funds. The transaction was described as planned, not completed.

• 2020-04-21

  Shengzhao Pharmaceutical and Hisun signed a contract manufacturing agreement[7]圣兆药物与海正药业签署委托生产协议hy.stock.cnfol.com

  Shengzhao Pharmaceutical announced that it had signed a contract manufacturing agreement with Hisun Pharmaceutical for two liposomal products.

• 2020-04-21

  圣兆药物 and 海正药业 expand active-ingredient cooperation[8]圣兆药物与海正药业扩大原料药合作finance.sina.com.cn

  Reported: 2020-04-23

  圣兆药物 and 海正药业 signed a contract under which 圣兆药物 commissioned 海正药业 to develop the production process for sterile aripiprazole monohydrate active ingredient. The companies will jointly produce process-validation batches at a contract manufacturing site designated by 圣兆药物.

• 2020-03-20

  Haizheng Pharma subsidiary and Anbisheng terminate cooperation agreements[9]海正药业孙公司与安必生终止合作协议finance.sina.com.cn

  Reported: 2020-03-20

  Haizheng Pharma announced that the parties reached a settlement and that their exclusive distribution, distribution-and-purchase, and supplemental agreements would terminate effective when the settlement agreement took effect.

1. 1Hisun Pharmaceutical Official Websitehisunpharm.com
2. 2数据完整性问题遭FDA进口禁令jiemian.com
3. 3数据完整性问题遭FDA进口禁令cs.com.cn
4. 4和剂药业完成A轮融资finance.sina.com.cn
5. 5上交所就海正药业重组预案信息披露发出问询sc.stock.cnfol.com
6. 6海正药业宣布筹划收购瀚晖制药49%股权finance.sina.com.cn
7. 7圣兆药物与海正药业签署委托生产协议hy.stock.cnfol.com
8. 8圣兆药物与海正药业扩大原料药合作finance.sina.com.cn
9. 9海正药业孙公司与安必生终止合作协议finance.sina.com.cn
10. 10和剂药业完成2.8亿元A轮融资，与美国Corvus Pharmaceuticals达成战略合作finance.sina.com.cn